Free Cash Flow Chart

Historical Free Cash Flow Data

View and export this data back to 2019. Start Trial.
Date Value
September 30, 2026 -398.24M
June 30, 2026 -372.77M
March 31, 2026 -383.84M
December 31, 2025 -360.05M
September 30, 2025 -352.36M
June 30, 2025 -355.57M
March 31, 2025 -360.96M
December 31, 2024 -356.19M
September 30, 2024 -145.37M
June 30, 2024 -153.40M
March 31, 2024 -169.28M
December 31, 2023 -182.93M
September 30, 2023 -391.86M
June 30, 2023 -380.41M
March 31, 2023 -353.49M
Date Value
December 31, 2022 -26.42M
September 30, 2022 39.49M
June 30, 2022 123.00M
March 31, 2022 148.21M
December 31, 2021 -113.08M
September 30, 2021 -133.96M
June 30, 2021 -155.22M
March 31, 2021 -131.72M
December 31, 2020 -112.10M
September 30, 2020 -99.64M
June 30, 2020 -94.01M
March 31, 2020 -86.75M
December 31, 2019 -84.52M
September 30, 2019 -78.75M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Intellia Therapeutics, Inc. -358.08M
Twist Bioscience Corp. -95.96M
Prime Medicine, Inc. -158.54M
Sarepta Therapeutics, Inc. 167.79M
Q32 Bio, Inc. -20.07M